Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Coles CE, Haviland JS, Kirby AM, Griffin CL, Sydenham MA, Titley JC et al, on behalf of the IMPORT Trial Management Group.
Lancet 2023; 401: 2124-2137.
A total of 2617 women were enrolled in the trial. Concomitant booster irradiation was safe, with similar rates of local recurrence: 2 per cent and 3.2 per cent in the different dosages, compared to 1.9 per cent in controls. Simultaneous booster irradiation reduced patient visits.
Comment: Easier for the women, and should improve treatment scheduling.
29 August 2023Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.